Switch theme
Sign up to access all valuation multiples
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
2005
20
Last FY Revenue $4.0M
Last FY EBITDA $5.7M
$25.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Biotechnology Assets achieved revenue of $4.0M and an EBITDA of $5.7M.
Biotechnology Assets expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biotechnology Assets valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $4.0M | XXX | XXX | XXX |
| Gross Profit | XXX | $3.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 97% | XXX | XXX | XXX |
| EBITDA | XXX | $5.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 142% | XXX | XXX | XXX |
| EBIT | XXX | $3.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | 83% | XXX | XXX | XXX |
| Net Profit | XXX | $1.8M | XXX | XXX | XXX |
| Net Margin | XXX | 44% | XXX | XXX | XXX |
| Net Debt | XXX | $7.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biotechnology Assets's stock price is EUR 0 (or $0).
Biotechnology Assets has current market cap of EUR 20.7M (or $23.2M), and EV of EUR 22.3M (or $25.1M).
See Biotechnology Assets trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25.1M | $23.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biotechnology Assets has market cap of $23.2M and EV of $25.1M.
Biotechnology Assets's trades at 6.2x EV/Revenue multiple, and 4.4x EV/EBITDA.
Equity research analysts estimate Biotechnology Assets's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biotechnology Assets's P/E ratio is not available.
See valuation multiples for Biotechnology Assets and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $23.2M | XXX | $23.2M | XXX | XXX | XXX |
| EV (current) | $25.1M | XXX | $25.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 4.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 7.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 13.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -80.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiotechnology Assets's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $29K for the same period.
Biotechnology Assets's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biotechnology Assets's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biotechnology Assets and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 142% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $29K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biotechnology Assets acquired XXX companies to date.
Last acquisition by Biotechnology Assets was XXXXXXXX, XXXXX XXXXX XXXXXX . Biotechnology Assets acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biotechnology Assets founded? | Biotechnology Assets was founded in 2005. |
| Where is Biotechnology Assets headquartered? | Biotechnology Assets is headquartered in Spain. |
| How many employees does Biotechnology Assets have? | As of today, Biotechnology Assets has 20 employees. |
| Is Biotechnology Assets publicy listed? | Yes, Biotechnology Assets is a public company listed on MAD. |
| What is the stock symbol of Biotechnology Assets? | Biotechnology Assets trades under BST ticker. |
| When did Biotechnology Assets go public? | Biotechnology Assets went public in 2011. |
| Who are competitors of Biotechnology Assets? | Similar companies to Biotechnology Assets include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biotechnology Assets? | Biotechnology Assets's current market cap is $23.2M |
| Is Biotechnology Assets profitable? | Yes, Biotechnology Assets is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
